MICHELLE MARTIN: Open Payments
NPI 1316555667 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 12 payments from 6 companies in 2025. Trend: 2023 $99 · 2024 $179 · 2025 $476
Food & beverage: $476
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 1 | $147 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $108 |
| Ipsen Biopharmaceuticals, Inc | 4 | $86 |
| Madrigal Pharmaceuticals | 3 | $78 |
| Mirum Pharmaceuticals, Inc. | 2 | $41 |
| Novo Nordisk Inc | 1 | $15 |
Products named: XIFAXAN, IQIRVO, REZDIFFRA, Livmarli, Wegovy.
Industry payments across TX — which companies pay providers there.
